Question: why was xigris pulled from the market?
Answer: Drotrecogin alfa. Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties. ... withdrew Xigris from the market after a major study showed no efficacy for the treatment of sepsis.